Signature · the flagship liquid-biopsy profile

Signature STb O+

523 genes for drivers, 59 for copy number, 23 for fusions, plus the complete immune and pharmacogenomic profile and the widest trial matching we offer.

01Comprehensive genomic profiling

The fullest liquid-biopsy picture

STb O+ leaves no clinically relevant stone unturned: broad driver coverage, fusions, copy number, the complete immune and pharmacogenomic profile, mutational signatures, and the widest reach for trial matching.

523genes for SNVs and InDels

59genes for copy number

23fusion genes

6intelligence layers, all populated

What comprehensive profiling means

Reading a large, curated set of cancer genes in depth, and combining several kinds of signal in one test: point mutations, insertions and deletions, fusions, copy-number changes, and genome-wide markers like TMB, MSI and mutational signatures.

The difference between finding the obvious drivers and understanding the whole tumour.

03Every gene on this test

The full panel

523 genes on the panel

Find a gene

SNVs and InDels

523 genes

The full comprehensive profiling gene set.

ABL1
ABL2
ACVR1
ACVR1B
AKT1
AKT2
AKT3
ALK
ALOX12B
ANKRD11
ANKRD26
APC
AR
ARAF
ARFRP1
ARID1A
ARID1B
ARID2
ARID5B
ASXL1
ASXL2
ATM
ATR
ATRX
AURKA
AURKB
AXIN1
AXIN2
AXL
B2M
BAP1
BARD1
BBC3
BCL10
BCL2
BCL2L1
BCL2L11
BCL2L2
BCL6
BCOR
BCORL1
BCR
BIRC3
BLM
BMPR1A
BRAF
BRCA1
BRCA2
BRD4
BRIP1
BTG1
BTK
C11orf30
CALR
CARD11
CASP8
CBFB
CBL
CCND1
CCND2
CCND3
CCNE1
CD274
CD276
CD74
CD79A
CD79B
CDC73
CDH1
CDK12
CDK4
CDK6
CDK8
CDKN1A
CDKN1B
CDKN2A
CDKN2B
CDKN2C
CEBPA
CENPA
CHD2
CHD4
CHEK1
CHEK2
CIC
CREBBP
CRKL
CRLF2
CSF1R
CSF3R
CSNK1A1
CTCF
CTLA4
CTNNA1
CTNNB1
CUL3
CUX1
CXCR4
CYLD
DAXX
DCUN1D1
DDR2
DDX41
DHX15
DICER1
DIS3
DNAJB1
DNMT1
DNMT3A
DNMT3B
DOT1L
E2F3
EED
EGFL7
EGFR
EIF1AX
EIF4A2
EIF4E
EML4
EP300
EPCAM
EPHA3
EPHA5
EPHA7
EPHB1
ERBB2
ERBB3
ERBB4
ERCC1
ERCC2
ERCC3
ERCC4
ERCC5
ERG
ERRFI1
ESR1
ETS1
ETV1
ETV4
ETV5
ETV6
EWSR1
EZH2
FAM123B
FAM175A
FAM46C
FANCA
FANCC
FANCD2
FANCE
FANCF
FANCG
FANCI
FANCL
FAS
FAT1
FBXW7
FGF1
FGF10
FGF14
FGF19
FGF2
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FGFR1
FGFR2
FGFR3
FGFR4
FH
FLCN
FLI1
FLT1
FLT3
FLT4
FOXA1
FOXL2
FOXO1
FOXP1
FRS2
FUBP1
FYN
GABRA6
GATA1
GATA2
GATA3
GATA4
GATA6
GEN1
GID4
GLI1
GNA11
GNA13
GNAQ
GNAS
GPR124
GPS2
GREM1
GRIN2A
GRM3
GSK3B
H3F3A
H3F3B
H3F3C
HGF
HIST1H1C
HIST1H2BD
HIST1H3A
HIST1H3B
HIST1H3C
HIST1H3D
HIST1H3E
HIST1H3F
HIST1H3G
HIST1H3H
HIST1H3I
HIST1H3J
HIST2H3A
HIST2H3C
HIST2H3D
HIST3H3
HLAA
HLAB
HLAC
HNF1A
HNRNPK
HOXB13
HRAS
HSD3B1
HSP90AA1
ICOSLG
ID3
IDH1
IDH2
IFNGR1
IGF1
IGF1R
IGF2
IKBKE
IKZF1
IL10
IL7R
INHA
INHBA
INPP4A
INPP4B
INSR
IRF2
IRF4
IRS1
IRS2
JAK1
JAK2
JAK3
JUN
KAT6A
KDM5A
KDM5C
KDM6A
KDR
KEAP1
KEL
KIF5B
KIT
KLF4
KLHL6
KMT2B
KMT2C
KMT2D
KRAS
LAMP1
LATS1
LATS2
LMO1
LRP1B
LYN
LZTR1
MAGI2
MALT1
MAP2K1
MAP2K2
MAP2K4
MAP3K1
MAP3K13
MAP3K14
MAP3K4
MAPK1
MAPK3
MAX
MCL1
MDC1
MDM2
MDM4
MED12
MEF2B
MEN1
MET
MGA
MITF
MLH1
MLL
MLLT3
MPL
MRE11A
MSH2
MSH3
MSH6
MST1
MST1R
MTOR
MUTYH
MYB
MYC
MYCL
MYCN
MYD88
MYOD1
NAB2
NBN
NCOA3
NCOR1
NEGR1
NF1
NF2
NFE2L2
NFKBIA
NKX21
NKX31
NOTCH1
NOTCH2
NOTCH3
NOTCH4
NPM1
NRAS
NRG1
NSD1
NTRK1
NTRK2
NTRK3
NUP93
NUTM1
PAK1
PAK3
PAK7
PALB2
PARK2
PARP1
PAX3
PAX5
PAX7
PAX8
PBRM1
PDCD1
PDCD1LG2
PDGFRA
PDGFRB
PDK1
PDPK1
PGR
PHF6
PHOX2B
PIK3C2B
PIK3C2G
PIK3C3
PIK3CA
PIK3CB
PIK3CD
PIK3CG
PIK3R1
PIK3R2
PIK3R3
PIM1
PLCG2
PLK2
PMAIP1
PMS1
PMS2
PNRC1
POLD1
POLE
PPARG
PPM1D
PPP2R1A
PPP2R2A
PPP6C
PRDM1
PREX2
PRKAR1A
PRKCI
PRKDC
PRSS8
PTCH1
PTEN
PTPN11
PTPRD
PTPRS
PTPRT
QKI
RAB35
RAC1
RAD21
RAD50
RAD51
RAD51B
RAD51C
RAD51D
RAD52
RAD54L
RAF1
RANBP2
RARA
RASA1
RB1
RBM10
RECQL4
REL
RET
RFWD2
RHEB
RHOA
RICTOR
RIT1
RNF43
ROS1
RPS6KA4
RPS6KB1
RPS6KB2
RPTOR
RUNX1
RUNX1T1
RYBP
SDHA
SDHAF2
SDHB
SDHC
SDHD
SETBP1
SETD2
SF3B1
SH2B3
SH2D1A
SHQ1
SLIT2
SLX4
SMAD2
SMAD3
SMAD4
SMARCA4
SMARCB1
SMARCD1
SMC1A
SMC3
SMO
SNCAIP
SOCS1
SOX10
SOX17
SOX2
SOX9
SPEN
SPOP
SPTA1
SRC
SRSF2
STAG1
STAG2
STAT3
STAT4
STAT5A
STAT5B
STK11
STK40
SUFU
SUZ12
SYK
TAF1
TBX3
TCEB1
TCF3
TCF7L2
TERC
TERT
TET1
TET2
TFE3
TFRC
TGFBR1
TGFBR2
TMEM127
TMPRSS2
TNFAIP3
TNFRSF14
TOP1
TOP2A
TP53
TP63
TRAF2
TRAF7
TSC1
TSC2
TSHR
U2AF1
VEGFA
VHL
VTCN1
WISP3
WT1
XIAP
XPO1
XRCC2
YAP1
YES1
ZBTB2
ZBTB7A
ZFHX3
ZNF217
ZNF703
ZRSR2

Copy-number variation

59 genes

Genes assessed for gains and losses.

AKT2
ALK
AR
ATM
BRAF
BRCA1
BRCA2
CCND1
CCND3
CCNE1
CDK4
CDK6
CHEK1
CHEK2
EGFR
ERBB2
ERBB3
ERCC1
ERCC2
ESR1
FGF1
FGF10
FGF14
FGF19
FGF2
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FGFR1
FGFR2
FGFR3
FGFR4
JAK2
KIT
KRAS
LAMP1
MDM2
MDM4
MET
MYC
MYCL
MYCN
NRAS
NRG1
PDGFRA
PDGFRB
PIK3CA
PIK3CB
PTEN
RAF1
RET
RICTOR
RPS6KB1
TFRC

Fusions and rearrangements

23 genes

ABL1
ALK
BCR
BRAF
CD74
EGFR
ETV1
ETV4
ETV6
EWSR1
FGFR2
FGFR3
NAB2
NTRK1
NTRK2
NUTM1
PAX3
PAX8
PPARG
RET
ROS1
TFE3
TMPRSS2

HLA genes

3 genes

Immune presentation genotype.

HLAA
HLAB
HLAC

Histone genes

16 genes

Including the H3 alterations seen in specific tumour types.

HIST1H1C
HIST1H2BD
HIST1H3A
HIST1H3B
HIST1H3C
HIST1H3D
HIST1H3E
HIST1H3F
HIST1H3G
HIST1H3H
HIST1H3I
HIST1H3J
HIST2H3A
HIST2H3C
HIST2H3D
HIST3H3

The groups below overlap. Copy-number, fusion, HLA and histone genes are all within the 523-gene panel, listed separately to show what each is assessed for.

When to choose it

Immunotherapy is the question

TMB and MSI are central to your decision.

Standard options are limited

You want the widest trial-matching reach.

You want the deepest analysis

Every intelligence layer, fully populated.

At this breadth, TrialGraph matches your exact profile to recruiting studies including early-phase targeted trials, and SynerGx evaluates rational drug combinations for future enrolment if standard therapies are exhausted.

Confirmed at consultation

Confirmed at consultation, with honest guidance on whether this breadth is the right investment for your case.

Research and evidence

The science behind this

Comprehensive genomic profiling from blood is validated and increasingly guideline-endorsed for advanced cancer.

Study 1

Blood-based profiling, extensively validated

A cfDNA comprehensive genomic profiling assay was validated across more than 7,500 tests and over 30,000 variants, spanning 300+ genes and 30+ cancer types.

Woodhouse R, et al. PLoS ONE, 2020.

Study 2

Guidelines support ctDNA profiling

NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue. ASCO recommends blood cfDNA as the specimen of choice for comprehensive profiling in advanced breast cancer.

Review, Cancers, 2022.

Study 3

Plasma genotyping finds more targets

Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.

Aggarwal C, et al. JAMA Oncology, 2019.

These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.

Being clear about our limits

What we do and do not do

What we DO

Deliver the fullest liquid-biopsy profile with immune and PGx
Populate every intelligence layer and the widest trial match
Report mutational signatures and copy-number changes
Feed the most complete, tumour-board-signed report

What we DON’T do

Diagnose or decide treatment on its own
Rule out disease from a negative result
Guarantee a matched trial will have a place
Guarantee drug availability, approval, cover or benefit

Plain-language glossary (9 terms)

Term	What it means
ctDNA	Circulating tumour DNA, tumour fragments in blood that a liquid biopsy reads.
SNV / InDel	A single-letter DNA change, or a small insertion or deletion.
Fusion	Two genes joined abnormally, creating a driver that is often highly treatable.
CNV	Copy-number variation, extra or missing copies of a gene.
TMB	Tumour mutational burden, how many mutations a tumour carries.
MSI / MMR	Signals of faulty DNA repair that often predict immunotherapy response.
PGx	Pharmacogenomics, how your genes affect the way you handle specific drugs.
Tumour fraction	How much of the blood DNA came from the tumour.
CCR	Complete coding region, meaning the whole gene is read rather than known hotspots.

Important information and regulatory status

Signature STb O+ is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.

A result is not a diagnosis and does not by itself decide treatment.
A “not detected” result does not rule out cancer or a genetic change.
Not all cancers release enough DNA into blood to be detected.
We cannot guarantee that a medicine will be available, approved, covered or effective.
Collection kits are for qualified phlebotomists. They are not for self-testing.
Confirmatory testing may be required.

Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal